Anti-fibrotic treatments, including anti-TGF-β therapy and targeting CAFs, have demonstrated important potential in the treatment of malignant tumors (Mohapatra et al., 2022; Li J. et al., 2023). This evidence concerns the gene TGFB1 and cancer.